From treatable traits to GETomics in airway disease: moving towards clinical practice
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
With the objective of accelerating progress in research and clinical practice relating to such a treatable traits approach, the Portraits event was convened in Barcelona, Spain, in November 2022.
Here, while reporting the key concepts that emerged from the discussions during the meeting, we review the current state of the art related to treatable traits and chronic respiratory diseases management, and we describe the possible actions that clinicians can take in clinical practice to implement the treatable traits framework.
Furthermore, we explore the new concept of GETomics and the new models of research in the field of COPD.
Puedes leer el artículo completo aquí: https://pubmed.ncbi.nlm.nih.gov/38232989/
Autores: Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí.
Noticias relacionadas
Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD: A Pilot Study
This study explores how changes in the respiratory microbiome relate to systemic inflammation in COPD patients. It highlights correlations between bacterial abundance, eosinophilic markers, and airflow limitation severity.
Telomere length in patients with bronchiectasis
This study investigates telomere length (TL) in bronchiectasis patients, comparing them to COPD patients and healthy controls. Findings show no significant TL reduction in bronchiectasis compared to controls, but a trend towards shorter TL in idiopathic cases. Further research is needed to understand TL’s role in bronchiectasis.
Pathophysiology and genomics of bronchiectasis
Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
II Edición de los Premios MERCO-OdS
Los Premios MERCO-OdS reconocen a los proyectos sanitarios, políticas hospitalarias y médicos más reputados de España en su segunda edición. En la gala se destacó al Dr. Àlvar Agustí García-Navarro por su liderazgo en Neumología
Chiesi PatienTalks 2024
Accede a la inscripción en Streaming de Chiesi PatienTalks 2024, que tendrá lugar el próximo 26 de Noviembre de 2024, de 16 a 19h
Uso limitado y posibles obstáculos para la implementación de herramientas de telemedicina para el manejo remoto de pacientes con EPOC entre los miembros de la SEPAR
La TM (telemedicina) podría ayudar en el tratamiento de la EPOC, pero aún queda un largo camino para poder implantar un sistema seguro a nivel nacional.
Artículos
COPD
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
Imagen obtenida en Canva Pro.